Doctor talking to patient about cryoablation - image

TRUSTED BY YOU, TRUSTED FOR A REASON.

Treat more AF patients efficiently

OVERCOME COVID-19 BACKLOG IN AF TREATMENT

We are committed to helping you treat AF safely, effectively and efficiently. As the impact of the COVID-19 pandemic continues to burden the healthcare system, we are all searching for solutions to help manage challenges as restrictions are eased:

  • Case cancellations
  • Long waiting lists for AF ablations
  • Limited ablation procedure capacity (staff, beds, lab availability)
  • Patients are afraid to come to the hospital for scheduled procedures

Learn from Prof Ehrlich how he is treating patients suffering from atrial fibrillation more efficiently during COVID-19 pandemic.

See how the Arctic Front™ Cardiac Cryoablation Catheter System (hereafter “cryoballoon”) can benefit electrophysiologists, hospitals and patients.

CRYOBALLOON LEARNING CURVE

There are currently 33 million people estimated to have Atrial Fibrillation (AF) globally, with 14-17 million AF patients anticipated in Europe by 2030.1  It is estimated that it costs €18 billion annually to treat AF across the UK, Germany, France, Spain, and Italy, most of which is due to hospitalisations.2

It can, therefore, be difficult for hospitals to respond to the increased demand for AF ablations in cases when there are budget limitations, limited staff and cath lab availability, and a high total cost of care per patient.

Cryoballoon has proven to be a significantly shorter and more reproducible procedure than radiofrequency (RF), which can result in:

  • 93% less cumulative overtime hours
  • 47% more days with time for extra cath lab cases3

THE EASE AND ECONOMIC IMPACT OF CRYOBALLOON ADOPTION

Watch Prof. Carlo de Asmundis summarise the findings from his latest studies about the impact of AF procedure duration predictability on EP lab resource needs and the learning curve associated with Cryoballoon.

The Ease and Impact of Cryoballoon Adoption - (15:03)

Prof. Dr. Carlo De Asmundis shares his findings on positive impacts to procedural practice as a result of adopting Medtronic cryoballoon.
More information (see more) Less information (see less)

Click here to access Prof de Asmundis’ “Why the Distribution Matters” publication abstract.

Click here to access Prof de Asmundis’ “Learning curve using the second-generation cryoballoon ablation” publication abstract.

Providencia et al. 2016 also demonstrated that Cryoballoon ablation has less inter-operator and inter-centre outcome variability compared to point-by-point RF ablation4

Click here to access the publication abstract.

TREAT MORE PATIENTS WITH AN EFFICIENT AF ABLATION PROCEDURE

OPTIMISE EP LAB RESOURCES - Prof Ehrlich´s approach

Watch the video below & learn how Prof. Joachim Ehrlich and his team at St. Josefs-Hospital in Wiesbaden, Germany doubled the number of AF ablation procedures per day within one year. They even performed eight AF ablations in one day on one occasion.

Optimizing EP Lab Efficiency with the Cryoballoon - (10:49)

Prof. Dr. Joachim Ehrlich shares the results and impact of their process optimization project for AF ablation.
More information (see more) Less information (see less)

Unlock EP lab capactiy - Dr. Brusich´s approach

In order to meet the growing demand for AF ablations, despite  resource constraints, Dr. Brusich and the team at University Clinical Centre Rijeka in Croatia optimised cath lab resources with careful planning and efficient procedures, such as Cryoballoon ablation. Such efforts enabled the team to avoid staff overtime and to perform four AF ablations and four complex device-related procedures in one cath lab in a single day.

References

1

Su WW, Reddy VY, Bhasin K, et al. Cryoballoon Ablation of Pulmonary Veins for Persistent Atrial Fibrillation: Results From the Multicenter STOP Persistent AF Trial.Heart Rhythm. Published online June 23, 2020.

2

Baker, C. House of Commons Library Briefing Paper. NHS Hey Statistics: England, May 2018. Number 7281, 21 May 2018

3

Mantovani L, et al. The burden of atrial fibrillation in the more populated European countries: perspectives from the GARFIELD-AF registry. Abstract presented ESC Congress 2017.

4

Kowalski M. et al. J Invasive Cardiol. 2016;28(5):176-82

5

Providencia R, et al. Results from a multicentre comparison of cryoballoon vs. radiofrequency ablation for paroxysmal atrial fibrillation: is cryoablation more reproducible? EP Europace. 2016;19(1):48-57. doi:10.1093/europace/euw080 Europace | Published on behalf of the European Society of Cardiology.

*

The commercial name of the Medtronic cryoballoon is Arctic FrontTM Cardiac Cryoablation Catheter System.